Mazdutide vs Survodutide
Mazdutide vs Survodutide: two late-stage GLP-1 + glucagon dual agonists. Innovent vs Boehringer Ingelheim development paths.
The verdict
Same drug class, different developers and timelines. Both are GLP-1 + glucagon dual agonists, where the glucagon arm adds a metabolic-rate boost on top of GLP-1 appetite control. Mazdutide (Innovent) is further along and already approved in China for obesity. Survodutide (Boehringer Ingelheim) is still working through global trials and draws extra interest for its liver-disease data. If availability is the deciding factor, Mazdutide is the one that's actually approved somewhere. Survodutide is the one to watch on the global and metabolic-liver front.
Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.
Survodutide is Boehringer Ingelheim's dual agonist (GLP-1 + glucagon), a competitor to Retatrutide. Stronger fat-burn signal than the GLP-1-only drugs because it activates glucagon, which boosts metabolic rate. Phase 2 data is promising. Once-weekly.
Which one should you pick?
Pick Mazdutide if users wanting a glp/glucagon agonist with cleaner side effect profile than survodutide reports or followers of chinese metabolic-drug development.
Pick Survodutide if users plateaued on glp-1-only drugs or people targeting >15% body weight loss.
Still torn between Mazdutide and Survodutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Common questions
- Can you stack Mazdutide with Survodutide?
- Neither entry lists the other as a stack partner. Each full entry has its own stacking notes.
- What's the dose difference between Mazdutide and Survodutide?
- Mazdutide: Start 3 mg weekly. Titrate to 6-9 mg over 4-week steps based on tolerance.
- Survodutide: Start 0.3 mg sub-q weekly. Titrate over 4-week steps up to 6.0 mg in trials.
- Is Mazdutide or Survodutide FDA approved?
- Mazdutide: Not FDA approved. Approved in China (2025, Innovent, brand Xinermei) for obesity and type 2 diabetes. Eli Lilly holds ex-China rights (LY-3305677) and runs US development (Phase 2).
- Survodutide: Investigational. Phase 3 trials by Boehringer Ingelheim and Zealand Pharma (co-developers).
- What are the side effects of Mazdutide vs Survodutide?
- Mazdutide: Nausea; Constipation or diarrhea; Mild fatigue.
- Survodutide: Nausea (especially titration steps); Diarrhea or constipation; Mild fatigue.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.